PubMed
LL-37, the only human member of the cathelicidin family of antimicrobial peptides
Vandamme et al., 2012
AntimicrobialResearch OnlyB
LL-37
Cathelicidin hCAP18
LL-37 is the only cathelicidin antimicrobial peptide expressed in humans, derived from cleavage of the C-terminus of hCAP18. It demonstrates broad-spectrum antimicrobial activity against bacteria (including MRSA), fungi, and viruses, and also plays critical roles in wound healing, immune modulation, and anti-tumor activity. Expressed primarily in neutrophils, epithelial cells, and skin. Research only.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 7
- Research grade
- B
- Experience
- 100
- Activity
- 92
Overall check-ins
Trackers & reports
Overview
About LL-37
LL-37 is the only cathelicidin antimicrobial peptide expressed in humans, derived from cleavage of the C-terminus of hCAP18. It demonstrates broad-spectrum antimicrobial activity against bacteria (including MRSA), fungi, and viruses, and also plays critical roles in wound healing, immune modulation, and anti-tumor activity. Expressed primarily in neutrophils, epithelial cells, and skin. Research only.
- Category
- Antimicrobial
- Regulatory status
- Research Only
- Also known as
- Cathelicidin hCAP18
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Self-reported dose per injection
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 100–400 mcg
100–200
4
200–400
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Cited research (5)
Source
PubMed
The antimicrobial peptide LL-37 inhibits biofilm formation
Dean et al., 2011
ClinicalTrials.gov
LL-37 studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Rosacea: Pathogenesis and Therapeutic Correlates
Geng et al., 2024
PubMed
LL-37 antimicrobial peptide: Molecular characterisation and its role in oral health and disease-A narrative review
Soman et al., 2026
Tools
Explore more
Explore
More ways to learn about LL-37 from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about LL-37?
This page summarizes 6 anonymized self-reports from PeptIQ users who track LL-37, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for LL-37?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for LL-37?
5 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is LL-37 safe to use?
This wiki does not assess safety or recommend use. LL-37 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of LL-37?
This wiki summarizes observational community reports and linked citations for LL-37. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for LL-37 for study-level context — not medical advice.
What is the legal status of LL-37?
LL-37 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of LL-37?
Safety data quality for LL-37 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on LL-37?
This page links 5 indexed sources for LL-37. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.